These authors subsequently evaluated changes to serum creatinine after treatment with cisplatin in human cancer patients (n = 78) according to the presence or absence of a copy of the nonsynonymous SLC22A2 rs316019 variant denoting reduced OCT2 function [20]. Here, SLC22A2 is linked to cancer.